 |
| Pfizer and AstraZeneca Covid-19 vaccines were effective against symptomatic Covid-19 infection in high risk groups |
Reuters
9/7/2021
LONDON: Public Health England (PHE) said on Friday Pfizer and AstraZeneca Covid-19 vaccines were effective against symptomatic Covid-19 infection in high risk groups, citing a pre-print study based on 1 million vulnerable people.
Overall vaccine effectiveness against symptomatic disease in risk groups was around 60% after one dose of either AstraZeneca or Pfizer-BioNTech with little difference by age, PHE said.
That rises to 81% for AstraZeneca following a second dose in people in risk groups aged 16 to 64, with no data available for Pfizer. Among those over 64, Pfizer was 89% effective and AstraZeneca 80% effective after the second dose, the health agency said.
"This real-world data shows for the first time that most people who are clinically vulnerable to Covid-19 still receive high levels of protection after 2 doses of vaccine," said Mary Ramsay, Head of Immunization at PHE.
LONDON: Public Health England (PHE) said on Friday Pfizer and AstraZeneca Covid-19 vaccines were effective against symptomatic Covid-19 infection in high risk groups, citing a pre-print study based on 1 million vulnerable people.
Overall vaccine effectiveness against symptomatic disease in risk groups was around 60% after one dose of either AstraZeneca or Pfizer-BioNTech with little difference by age, PHE said.
That rises to 81% for AstraZeneca following a second dose in people in risk groups aged 16 to 64, with no data available for Pfizer. Among those over 64, Pfizer was 89% effective and AstraZeneca 80% effective after the second dose, the health agency said.
"This real-world data shows for the first time that most people who are clinically vulnerable to Covid-19 still receive high levels of protection after 2 doses of vaccine," said Mary Ramsay, Head of Immunization at PHE.
